Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

D. Rischin, N. I. Khushalani, C. D. Schmults, A. Guminski, A. L. S. Chang, K. D. Lewis, A. M. Lim, L. Hernandez-Aya, B. G. M. Hughes, D. Schadendorf, A. Hauschild, E. Stankevich, J. Booth, S. Li, Z. Chen, J. Desai, I. Lowy, M. G. Fury, M. R. Migden

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Number of pages2
JournalAnnals of Oncology
Publication statusPublished - Dec 2019
Externally publishedYes
EventImmuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) - Geneva, Switzerland
Duration: 11 Dec 201914 Dec 2019

Cite this